Tumor-associated MerTK promotes a pro-inflammatory microenvironment and enhances immune checkpoint inhibitor response in triple-negative breast cancer
These preclinical findings indicate that MerTK could serve as an independent predictive biomarker for ICI response in TNBC, potentially expanding the cohort of late-stage TNBC patients eligible for ICI therapy while reducing toxicity in early-stage patients by treating only those predicted to respond.
Authors
- Terry D. Juang
- Ravi Salgia (ORCID: https://orcid.org/0000-0001-9643-7626)
- Roxana Alexandridis
- Christine E. Glitchev
- Jillian M. Adams
- Deric L. Wheeler (ORCID: https://orcid.org/0000-0001-5915-3675)
- Sheena C. Kerr (ORCID: https://orcid.org/0000-0002-4404-3382)
- Irene Kang (ORCID: https://orcid.org/0000-0002-9472-3853)
- Meredith Hyun (ORCID: https://orcid.org/0000-0003-2285-4026)
- David T. Yang (ORCID: https://orcid.org/0000-0002-9488-1704)
- Mari Iida (ORCID: https://orcid.org/0000-0001-7168-8680)
- Bridget E. Crossman (ORCID: https://orcid.org/0009-0006-8274-9104)
- Candie Y Lin
- Regan L. Harmon
Institutions
- University of Wisconsin–Madison (US)
- University of Wisconsin Carbone Cancer Center (US)
- City of Hope (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-05
- DOI
- https://doi.org/10.3389/fonc.2025.1579214
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Cancer Institute